- Home
- Products
- Customized ADCs
- FZD1
- Anti-FZD1 (Vantictumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-FZD1 (Vantictumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1183)
This ADC product is comprised of an anti-FZD1 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- FZD1
- Alternative Names
- FZD1; frizzled family receptor 1; frizzled (Drosophila) homolog 1 , frizzled 1, seven transmembrane spanning receptor , frizzled homolog 1 (Drosophila); frizzled-1; DKFZp564G072; frizzled; Drosophila; homolog of; 1; Wnt receptor; fz-1; fzE1; hFz1; frizzled homolog 1; frizzled, Drosophila, homolog of, 1; frizzled 1, seven transmembrane spanning receptor; FLJ95923;
- Target Entrez Gene ID
- 8321
- Target UniProt ID
- Q9UP38
- Overview
- Members of the 'frizzled' gene family encode 7-transmembrane domain proteins that are receptors for Wnt signaling proteins. The FZD1 protein contains a signal peptide, a cysteine-rich domain in the N-terminal extracellular region, 7 transmembrane domains, and a C-terminal PDZ domain-binding motif. The FZD1 transcript is expressed in various tissues.
- Overview
- Human Anti-FZD1 IgG2-lambda antibody, Vantictumab
- Generic name
- Vantictumab
- Host animal
- Human
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-MUC1 (clone hPAM4)-SN-38 ADC (CAT#: ADC-W-090)
- Anti-C5 (Eculizumab)-SPDB-DM4 ADC (CAT#: ADC-W-729)
- Anti-TNFRSF10B (Conatumumab)-MC-MMAF ADC (CAT#: ADC-W-1864)
- Anti-DLL3-PBD ADC (CAT#: ADC-W-558)
- Anti-MUC16 (Sofituzumab)-VC-MMAE ADC (CAT#: ADC-W-427)
- Anti-VEGFA (Vanucizumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2292)
- Anti-C. diff toxin B (Bezlotoxumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2064)
- Anti-IL13 (Anrukinzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1299)
- Anti-CD22 (clone 10F4v1)-SMCC-DM1 ADC (CAT#: ADC-W-182)
- Anti-CA9 (Girentuximab)-SPDB-DM4 ADC (CAT#: ADC-W-741)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1183. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
CAT# | Product Name | Linker | Payload |
ADC-W-1180 | Anti-FZD1 (Vantictumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
ADC-W-1178 | Anti-FZD1 (Vantictumab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
ADC-W-1179 | Anti-FZD1 (Vantictumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
ADC-W-1182 | Anti-FZD1 (Vantictumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
ADC-W-1181 | Anti-FZD1 (Vantictumab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
CAT# | Product Name | Linker | Payload |
ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2594 | Anti-EGFR (Cetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
CAT# | Product Name | Linker | Payload |
ADC-W-2570 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2615 | Anti-MS4A1 (Rituximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
ADC-W-2542 | Anti-CD33 (Gemtuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.